Johnson & Johnson $JNJ Shares Sold by Arvest Investments Inc.

Key Points

• Arvest Investments Inc. reduced its stake in Johnson & Johnson by 19.6%, selling 2,900 shares during the second quarter, leaving them with 11,924 shares valued at approximately $1.82 million.
• Multiple institutional investors, including Highline Wealth Partners LLC and Stone House Investment Management LLC, have made recent adjustments to their positions in JNJ, with 69.55% of the stock currently held by institutional investors.
• The company declared a quarterly dividend of $1.30 per share, resulting in an annualized yield of 2.9%, reflecting a payout ratio of 55.61%.

Arvest Investments Inc. cut its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 19.6% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 11,924 shares of the company's stock after selling 2,900 shares during the period. Arvest Investments Inc.'s holdings in Johnson & Johnson were worth $1,821,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in JNJ. Highline Wealth Partners LLC increased its position in shares of Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock valued at $42,000 after acquiring an additional 86 shares during the last quarter. Stone House Investment Management LLC acquired a new stake in shares of Johnson & Johnson during the first quarter valued at about $47,000. 1248 Management LLC acquired a new stake in shares of Johnson & Johnson during the first quarter valued at about $48,000. von Borstel & Associates Inc. acquired a new stake in shares of Johnson & Johnson during the first quarter valued at about $49,000. Finally, Capital A Wealth Management LLC acquired a new stake in shares of Johnson & Johnson during the fourth quarter valued at about $50,000. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In related news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction on Thursday, September 4th. The shares were sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is currently owned by company insiders.

Analyst Ratings Changes

A number of brokerages recently weighed in on JNJ. Erste Group Bank upgraded shares of Johnson & Johnson from a "hold" rating to a "buy" rating in a report on Wednesday, July 23rd. Piper Sandler restated an "overweight" rating on shares of Johnson & Johnson in a report on Thursday, July 17th. Morgan Stanley lifted their price objective on shares of Johnson & Johnson from $171.00 to $176.00 and gave the company an "equal weight" rating in a report on Thursday, July 17th. Guggenheim restated a "neutral" rating and issued a $167.00 price objective (up previously from $164.00) on shares of Johnson & Johnson in a report on Thursday, July 17th. Finally, UBS Group lifted their price objective on shares of Johnson & Johnson from $180.00 to $190.00 and gave the company a "buy" rating in a report on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, Johnson & Johnson presently has a consensus rating of "Moderate Buy" and an average target price of $176.29.

Johnson & Johnson Stock Down 0.2%

JNJ stock opened at $178.10 on Friday. The company has a fifty day moving average price of $170.81 and a 200 day moving average price of $161.29. Johnson & Johnson has a 12 month low of $140.68 and a 12 month high of $181.16. The company has a market cap of $428.93 billion, a price-to-earnings ratio of 19.05, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.01 and a quick ratio of 0.76.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last released its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, beating the consensus estimate of $2.68 by $0.09. Johnson & Johnson had a net margin of 25.00% and a return on equity of 32.49%. The firm had revenue of $23.74 billion during the quarter, compared to the consensus estimate of $22.85 billion. During the same quarter in the prior year, the firm earned $2.82 EPS. Johnson & Johnson's revenue for the quarter was up 5.8% on a year-over-year basis. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Sell-side analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 9th. Investors of record on Tuesday, August 26th were given a $1.30 dividend. The ex-dividend date was Tuesday, August 26th. This represents a $5.20 annualized dividend and a yield of 2.9%. Johnson & Johnson's dividend payout ratio is 55.61%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.